Early Phase I Study of A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
Summary
The purpose of this early phase I study is to determine the safety and efficacy of cobimetinib, olaparib, temuterkib, or onvansertib works in patients with pancreatic cancer.
General Information
NCT#: NCT04005690
Study ID: STUDY00019211
Trial Phase: Phase I
Trial Sponsor: Oregon Health & Science University Knight Cancer Institute
Therapies Used in This Trial: Olaparib, Cobimetinib, Onvansertib, temuterkib